Health Catalyst , Inc. (NASDAQ:HCAT) recently disclosed a notable transaction by one of its top executives. Linda Llewelyn, the company's Chief People Officer, sold 2,005 shares of Health Catalyst common stock at a price of $6.11 per share. The transaction, which took place on April 15, 2024, resulted in a total sale value of over $12,250. Following the sale, Llewelyn retains ownership of 126,226 shares in the company.
The sale was executed in accordance with a pre-arranged trading plan, known as a 10b5-1 plan, which Llewelyn had adopted on May 23, 2023. Such plans allow company insiders to set up a predetermined schedule for buying and selling shares to avoid accusations of trading on nonpublic information.
Investors often monitor insider transactions as they can provide insights into an executive's confidence in the company's future performance. However, it's important to note that insider sales can be motivated by a variety of personal financial considerations and do not necessarily reflect a negative outlook on the company's prospects.
Health Catalyst, Inc., based in South Jordan, Utah, specializes in providing data and analytics technology and services to healthcare organizations. The company's stock trades on the NASDAQ under the ticker symbol HCAT.
This latest transaction was publicly filed with the Securities and Exchange Commission and is accessible to investors for review. The filing ensures transparency in the trading activities of company insiders, providing the market with pertinent information.
InvestingPro Insights
As investors evaluate the recent insider transaction at Health Catalyst, Inc. (NASDAQ:HCAT), current financial metrics and analyst insights from InvestingPro can provide a broader context. The company has a market capitalization of approximately $329.12 million, demonstrating its size within the industry. Despite recent challenges, Health Catalyst's revenue has grown by 7.13% over the last twelve months as of Q4 2023, indicating potential resilience and adaptability in its operations.
InvestingPro Tips reveal that Health Catalyst holds more cash than debt on its balance sheet, which may provide a cushion in volatile market conditions. Additionally, analysts have revised their earnings upwards for the upcoming period, signaling potential optimism in the company's financial trajectory. Notably, there are 11 more InvestingPro Tips available, which could be essential for investors seeking a comprehensive understanding of Health Catalyst's performance and prospects. To access these insights, use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.
Among the key financial data points, Health Catalyst's price/book ratio stands at 0.9 as of the last twelve months ending Q4 2023, which might interest value-oriented investors. However, the company's P/E ratio is negative at -3.93, reflecting its lack of profitability over the same period. This aligns with an InvestingPro Tip that notes the company was not profitable over the last twelve months but is expected to turn a profit this year.
With the next earnings date scheduled for May 7, 2024, and the stock trading near its 52-week low, investors might consider these insights as they assess the potential risks and opportunities associated with Health Catalyst's stock.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.